Related references
Note: Only part of the references are listed.Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy
Chien-Hung Chen et al.
HEPATOLOGY INTERNATIONAL (2020)
The Yin and the Yang of Treatment for Chronic Hepatitis B-When to Start, When to Stop Nucleos(t)ide Analogue Therapy
Samuel Hall et al.
VIRUSES-BASEL (2020)
Single hepatocytes show persistence and transcriptional inactivity of hepatitis B
Ashwin Balagopal et al.
JCI INSIGHT (2020)
Promoting hospital and primary care collaboration for timely and effective care for chronic hepatitis B in western Melbourne
Katherine Sievert et al.
AUSTRALIAN HEALTH REVIEW (2020)
The Incidence of Hepatitis B Surface Antigen Loss Between Hepatitis B E Antigen-Negative Noncirrhotic Patients Who Discontinued or Continued Entecavir Therapy
Chien-Hung Chen et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study)
Kin Seng Liem et al.
GUT (2019)
Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis
Yee Hui Yeo et al.
GASTROENTEROLOGY (2019)
Global progress on the elimination of viral hepatitis as a major public health threat: An analysis of WHO Member State responses 2017
Shanley Smith et al.
JHEP REPORTS (2019)
Less can be more: A finite treatment approach for HBeAg-negative chronic hepatitis B
Pietro Lampertico et al.
HEPATOLOGY (2018)
Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B
Wen-Juei Jeng et al.
HEPATOLOGY (2018)
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
Norah A. Terrault et al.
HEPATOLOGY (2018)
Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B
Franziska Rinker et al.
JOURNAL OF HEPATOLOGY (2018)
DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B
George Papatheodoridis et al.
ANTIVIRAL THERAPY (2018)
Adherence to Nucleos(t)ide Analogue Therapies for Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis
Nathan Ford et al.
HEPATOLOGY COMMUNICATIONS (2018)
Management of Hepatitis B Virus (HBV) in transplantation
Clothilde Miaglia et al.
VIROLOGIE (2018)
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
JOURNAL OF HEPATOLOGY (2017)
Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study
Thomas Berg et al.
JOURNAL OF HEPATOLOGY (2017)
Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy
C. -H. Hung et al.
JOURNAL OF VIRAL HEPATITIS (2017)
Discontinuation of oral antivirals in chronic hepatitis B: A systematic review
George Papatheodoridis et al.
HEPATOLOGY (2016)
Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B
Christoph Hoener zu Siederdissen et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
Tung-Hung Su et al.
LIVER INTERNATIONAL (2016)
Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis
Y. C. Chen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection
T. -C. Tseng et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naive chronic hepatitis B patients in the real-world setting
R. Idilman et al.
JOURNAL OF VIRAL HEPATITIS (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
David Moher et al.
SYSTEMATIC REVIEWS (2015)
Antiviral Therapy of Chronic Hepatitis B
Florian van Boemmel et al.
INTERVIROLOGY (2014)
Off-Therapy Durability of Response to Entecavir Therapy in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients
Wen-Juei Jeng et al.
HEPATOLOGY (2013)
Long-Term Entecavir Treatment Reduces Hepatocellular Carcinoma Incidence in Patients With Hepatitis B Virus Infection
Tetsuya Hosaka et al.
HEPATOLOGY (2013)
A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-na⟨ve and -experienced adult Taiwanese chronic hepatitis B patients
Chien-Hung Chen et al.
HEPATOLOGY INTERNATIONAL (2013)
A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection
Jessica Liu et al.
JOURNAL OF HEPATOLOGY (2013)
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
George Papatheodoridis et al.
JOURNAL OF HEPATOLOGY (2012)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
Andreas Stang
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2010)
Clearance of Hepatitis B Surface Antigen and Risk of Hepatocellular Carcinoma in a Cohort Chronically Infected with Hepatitis B Virus
Josephine Simonetti et al.
HEPATOLOGY (2010)
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
David Moher et al.
INTERNATIONAL JOURNAL OF SURGERY (2010)
The Duration of Lamivudine Therapy for Chronic Hepatitis B: Cessation vs. Continuation of Treatment After HBeAg Seroconversion
James Fung et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Chronic Hepatitis B: Update 2009
Anna S. F. Lok et al.
HEPATOLOGY (2009)
Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients
A Matsumoto et al.
HEPATOLOGY RESEARCH (2005)
A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States
Emmet B. Keeffe et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects
MF Yuen et al.
HEPATOLOGY (2004)
Lamivudine for patients with chronic hepatitis B and advanced liver disease
YF Liaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
